AbelsonTaylor Elevates Beth Carik to Senior Vice President of Human Resources
Health and wellness advertising agency AbelsonTaylor promoted Beth Carik to senior vice president of human resources.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Eli Lilly and Pfizer End Tanezumab Development
/in Business, Clinical Trials, Complete Response Letter, European Medicines Agency (EMA), FDA, Nerve Growth Factor (NGF) Protein, Osteoarthritis, Osteoarthritis Pain, Partnerships, R&DEli Lilly and Pfizer announced Oct. 27 that they ceased the development of tanezumab, a pain drug the two companies had been developing for osteoarthritis.
Teva and MODAG Tie Up on Potential Parkinson’s, MSA Treatment
/in Business, Clinical Trials, Collaborations, Deals, Multiple system atrophy (MSA), Neurodegenerative Diseases, Parkinson’s disease, Quarterly results, R&D, TevaTeva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.
Trial For World’s First Potential Breast Cancer Vaccine Begins
/in Cancer Vaccines, Cleveland Clinic, Clinical Trials, Department of Defense, R&D, Triple Negative Breast Cancer (TNBC)Researchers at the Cleveland Clinic are set to launch a Phase I trial for what could be the first-ever vaccine to prevent triple-negative breast cancer.
Ocugen Hopes to Launch U.S. Phase III Trial of Covaxin
/in Bharat Biotech, Clinical Data, Clinical Trials, Coronavirus Vaccines, Covaxin (Bharat Biotech and ICMR), Investigational New Drug (IND) applications, R&DMalvern, Pa.-based Ocugen submitted an Investigational New Drug Application to the U.S. Food and Drug Administration to run a Phase III trial of India’s Covid-19 vaccine BBV152 (Covaxin).
Phase III Kidney Transplant Study Fails
/in Clinical Data, Clinical Trial Endpoints, Clinical Trials, Primary Endpoints, R&D, Renal transplants, Secondary Endpoints, Small Molecules, TransplantsAngion Biomedica and Vifor Pharma announced that their Phase III trial on ANG-3777 for renal transplant patients did not meet the study’s primary and secondary endpoints.
Merck signs pact to broaden generic manufacturing of COVID-19 pill
/in Agreements, Business, Facilities/Sites/Manufacturing, Generics, Licensing, Low-Income Countries, Medicines Patent Pool, Merck, Middle-Income Countries, R&D, United NationsMerck & Co. signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of the company’s experimental oral antiviral Covid-19 treatment, the U.S. drugmaker and the organization announced on Oct. 27.
Novavax seeks UK authorization for COVID-19 vaccine
/in Clinical Trials, COVID-19 Vaccinations, Efficacy Data, Novavax, R&D, Serum Institute of India, United Kingdom, World Health OrganizationNovavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.
FDA Vaccine Panel Recommends Pfizer-BioNTech Vaccine for Kids Ages 5-11
/in Advisory Committees, BNT162b2 (Pfizer and BioNTech), CDC, COVID-19 Vaccines, Efficacy Data, Emergency Use Authorization (EUA), FDA, Kids, Polls, Vaccines and Related Biological Products Advisory CommitteeThe U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for children 5 through 11 years of age, with 17 members voting yes and one abstention.
Raytheon warns of worker losses as companies impose vaccine mandate
/in Business, CNBC, COVID vaccine mandates, COVID-19 Vaccinations, Job Cuts, Joe Biden, U.S. Army, U.S. Labor DepartmentRaytheon Technologies’ top boss warned on Oct. 26 that the U.S. aerospace and defense firm will lose ‘several thousand’ employees who refused to take Covid-19 vaccines, as the company prepares to meet the Biden administration’s Dec. 8 deadline for immunization.